Why Bigtincan, Opthea, Seven West Media, & Telix shares are charging higher

The market may be trading lower but these ASX share aren’t…
The post Why Bigtincan, Opthea, Seven West Media, & Telix shares are charging higher appeared first on The Motley Fool Australia. –

In early afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is out of form and trading lower. At the time of writing, the benchmark index is down 0.3% to 7,363.5 points.

Four ASX shares that are not letting that hold them back are listed below. Here’s why they are charging higher:

Bigtincan Holdings Ltd (ASX: BTH)

The Bigtincan share price has jumped 11% to $1.13. This morning the sales enablement platform provider announced a small acquisition and revealed that it is on track to surpass its annualised recurring revenue guidance in FY 2021. In respect to the former, Bigtincan is acquiring Vidinoti SA for ~$770,000. Vidinoti is a leader in augmented and virtual reality systems and has developed a comprehensive suite of tools to create, deploy, and manage augmented reality content.

Opthea Ltd (ASX: OPT)

The Opthea share price has surged 17% higher to $1.65. Investors have been buying this biotech company’s shares following an update from rival Clearside Biomedical. That update reveals that Clearside Biomedical’s Phase 1/2a trial of its wet age-related macular degeneration (wet AMD) candidate has been successful. This news appears to have brought Opthea onto the radar of investors because both companies are developing drugs that target wet AMD. However, Opthea is well ahead and undertaking a phase 3 trial at present.

Seven West Media Ltd (ASX: SWM)

The Seven West Media share price has rocketed 17% higher to 47.5 cents. This morning the media company revealed that trading conditions have been very strong during the fourth quarter of FY 2021. According to the release, management expects fourth quarter advertising revenue to increase by 45% over the prior corresponding period. Seven West Media also revealed that full year operating earnings are expected to come in ahead of analyst consensus estimates.

Telix Pharmaceuticals Ltd (ASX: TLX)

The Telix share price is up 3.5% to $5.82. This follows an update on its meeting with the U.S. Food and Drug Administration in relation to its new drug application review for its Illuccix product. Positively, the FDA indicated that there are no outstanding substantive review issues with Telix’s submission. As a result, management is preparing for a launch, pending final approval.

The post Why Bigtincan, Opthea, Seven West Media, & Telix shares are charging higher appeared first on The Motley Fool Australia.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of May 24th 2021

More reading

Seven West (ASX:SWM) share price zooms 11% on trading update
Why the Opthea (ASX:OPT) share price is rocketing 12% higher
Telix (ASX:TLX) share price lower despite key FDA update
Bigtincan (ASX:BTH) share price jumps 7% on acquisition and guidance update
3 unloved ASX shares set to take off: analysts

James Mickleboro owns shares of Telix. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended BIGTINCAN FPO. The Motley Fool Australia owns shares of and has recommended BIGTINCAN FPO. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!